Last reviewed · How we verify
PER-001 Intravitreal Implant - Low Dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
PER-001 Intravitreal Implant - Low Dose (PER-001 Intravitreal Implant - Low Dose) — Perfuse Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PER-001 Intravitreal Implant - Low Dose TARGET | PER-001 Intravitreal Implant - Low Dose | Perfuse Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PER-001 Intravitreal Implant - Low Dose CI watch — RSS
- PER-001 Intravitreal Implant - Low Dose CI watch — Atom
- PER-001 Intravitreal Implant - Low Dose CI watch — JSON
- PER-001 Intravitreal Implant - Low Dose alone — RSS
Cite this brief
Drug Landscape (2026). PER-001 Intravitreal Implant - Low Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/per-001-intravitreal-implant-low-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab